Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound

This article was originally published here

The partnership between Boehringer Ingelheim and Lupin will develop LNP3794 as a potential targeted therapy for patients with difficult-to-treat cancers. The companies will develop the MEK inhibitor compound

The post Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply